@drjonlim
Senior Lecturer & Consultant Medical Oncologist in Advanced #Immunotherapy + #CellTherapy at @manchester.ac.uk & The Christie โข RISE Lead & MANIFEST Deputy Lead โข ESMO #TranslationalResearch Faculty ๐ Bio: bit.ly/Christie_JLim (tennis enthusiast ๐พ)
Do you have an impactful research idea?
One that could improve care or advance science?
Apply for the ESMO Leadership & Career Development Award, offering protected research time, leadership & communication training by 3 May 26 .
๐https://ow.ly/Gicm50YqcbZ
#Oncology #ESMOYOC
The Crick Postdoctoral Clinical Fellowship has been one of the most pivotal steps in my development as a clinical academic.
The environment, mentorship, infrastructure, and scientific ambition at @crick.ac.uk are truly unparalleled.
Strongly recommended! Deadline: 30th April ๐
Grateful to ๐๐ณ ๐ ๐๐ข๐ฏ๐ค๐ฆ๐ณ for the kind feature in their ๐๐บ๐ฒ๐ฟ๐ด๐ถ๐ป๐ด ๐๐ฒ๐ฎ๐ฑ๐ฒ๐ฟ๐ collection. Thank you to the editors for the nomination ๐.
Like many things, this really reflects teamwork & collaboration with many generous colleagues. Our perspective on TIL therapy in melanoma is now out #OpenAccess ๐
Man in a dark blue patterned shirt leaning on a window ledge inside a bright, modern corridor with large windows.
Professor Ludwig Dubois joins the MCRC & @manchester.ac.uk @fbmh-uom.bsky.social
as Chair in Experimental & Translational Radiobiology.
Heโll spearhead research into proton beam therapy & FLASH treatments to improve patient outcomes.
Read more: https://ow.ly/1k5g50YkUEn
Our new perspective just out in ๐๐ณ๐ช ๐ ๐๐ข๐ฏ๐ค๐ฆ๐ณ on TIL therapy in melanoma.
As TIL move closer to real-world use, the ๐ฉ๐ฐ๐ธ matters as much as the ๐ธ๐ฉ๐ฆ๐ต๐ฉ๐ฆ๐ณ. We reflect on the near future & the practical challenges of moving from trials to routine care.
Keen to hear thoughts/experiences from others๐
Come and join us at the ESMO Preceptorship on CUP! @worldcupalliance.bsky.social spread the word!
๐ New PhD Opportunity
An exciting PhD opportunity at the Cancer Research UK Manchester Centre, supporting the next generation of leaders in cancer research.
๐
Deadline: Friday 3 April
๐ For further information & to apply: ow.ly/ZWYs50Y7vHR
@uom-dcs.bsky.social
@manchester.ac.uk
๐...cutting-edge science, clinical insights & discussions re: real-world implementation of TIL therapy.
Featuring keynote speakers:
Inge Marie Svane ๐ฉ๐ฐ & Sebastian Klobuch ๐ณ๐ฑ.
@sklobuch.bsky.social
@debrajosephs.bsky.social
@turajliclab.bsky.social
@beckilee.bsky.social
๐ฃ Final agenda confirmed - only 5 weeks to go!
Join us on ๐ญ๐ญ ๐ ๐ฎ๐ฟ๐ฐ๐ต ๐ฎ๐ฌ๐ฎ๐ฒ in Manchester ๐ for our inaugural TIL Summit: Unlocking TIL Therapy โ A New Era for Melanoma Care in the UK.
Kindly sponsored by The Christie Charity.
Space limited - so don't miss out! For further information & to register:
One of the projects Iโm most proud of since returning to Manchester.
In awe of the resilience of our Ukrainian colleagues delivering cancer care under extraordinary circumstances, and grateful for the generosity of #TeamManchester colleagues in sharing best practice.
๐ฌ๐ง ๐ค ๐บ๐ฆ
Find out more ๐
New Journal for ImmunoTherapy of Cancer review: Steroid-sparing strategies for managing immune-related adverse events jitc.bmj.com/content/14/1...
lab to life
Exciting conference alert!
sites.manchester.ac.uk/from-lab-to-...
Fantastic speakers includingย Chris Marine, Christian Blank
Melanoma evolution
Local microenvironment of melanoma
Melanoma-host interactions
Precision immunotherapy
Emerging therapeutics
Clinical trials and real-world data
๐ For further details (deadline 3 June 2026):
www.esmo.org/meeting-cale...
๐ New on the ESMO events calendar for 2026!
Mark your calendar for the ๐๐ฆ๐ ๐ข ๐ฃ๐ฟ๐ฒ๐ฐ๐ฒ๐ฝ๐๐ผ๐ฟ๐๐ต๐ถ๐ฝ ๐ผ๐ป ๐ง๐๐บ๐ผ๐๐ฟ-๐๐ด๐ป๐ผ๐๐๐ถ๐ฐ ๐๐ฎ๐ป๐ฐ๐ฒ๐ฟ๐ ๐ฎ๐ป๐ฑ ๐๐ฎ๐ป๐ฐ๐ฒ๐ฟ ๐ผ๐ณ ๐จ๐ป๐ธ๐ป๐ผ๐๐ป ๐ฃ๐ฟ๐ถ๐บ๐ฎ๐ฟ๐ (๐๐จ๐ฃ) in Zurich: 18-19 September 2026.
Chaired by the fantastic @oncocook.bsky.social & @benwestphalen.bsky.social.
@myesmo.bsky.social
This is one of the projects Iโm most proud of since coming back to (re-)join #TeamManchester faculty. Delighted to welcome and host our Medical Oncology colleagues from UNCI, Kyiv at The Christie.
๐บ๐ฆ ๐ค ๐ฌ๐ง
Youโre such an inspiration, Adam! Keep going ๐.
๐ Kicking off the new year with our next #ChristieFellowship session!
How do we communicate science well - to patients, the public, and on social media?
Join us for an interactive session on ๐ฃ๐๐ฏ๐น๐ถ๐ฐ ๐๐ผ๐บ๐บ๐๐ป๐ถ๐ฐ๐ฎ๐๐ถ๐ผ๐ป with Prof @achoud72.bsky.social.
@christieinstitute.bsky.social
@mcrcnews.bsky.social
Thanks to @acir-org.bsky.social for highlighting our article!
Really grateful to you, Evangelos! Your mentorship, guidance and friendship in the lab made a huge difference, especially early on as a new PhD fellow ๐ค.
Looking forward to continuing to work closely together in Manchester! ๐
@uom-dcs.bsky.social
@mcrcnews.bsky.social
@cruk-mi.bsky.social
โCross-presentation shapes neoantigen visibility and cancer immunogenicity in #NatureImmunology๐คฏ
www.nature.com/articles/s41...
Huge congratulations @drjonlim.bsky.social ๐ฅ
Inspired and so lucky to have you in #Manchester ๐
Congratulations to #OliverSchulz, @reisesousalab.bsky.social , @crick.ac.uk
NB 'An important function of the immune system is to eradicate pre-malignant and malignant cells in the early phase of tumor development. For this reason, the use of carcinogens rather than transplantable tumor cell lines in mice can offer a more refined experimental approach (...)'
...and follow this thread ๐งต for how the story evolved:
How does the immune system decide which tumour antigens remain visible over timeโ
Our study on dendritic cell cross-presentation of dead-cell, F-actinโassociated antigens, and its impact on tumour immunogenicity and cancer evolution, was featured in @acir-org.bsky.social.
Read further here ๐
๐ค Do patients with cancer and clinicians see disease status the same way?
Our study highlights where understanding aligns - and where it doesnโt - underscoring the importance of clear communication in palliative care.
Presented first at #ESMOGI24, now published in full:
doi.org/10.1007/s003...
๐จ NEW opportunity! ๐จ
Weโre recruiting a Translational Research Programme Manager to support delivery of the recently launched MRC-funded ๐ฅ๐๐ฆ๐ programme at @uom-dcs.bsky.social @manchester.ac.uk - based in the Withington campus.
๐๏ธ Deadline: 30th January 2026.
๐ To find out more and to apply:
We cover:
โข TCR-T, CAR-T, TIL & NK-cell approaches
โข Lessons from early clinical studies
โข Key biological & practical challenges
โข Where the field may be heading next
Will cell therapy work in sarcomaโ
#Sarcoma #CellTherapy #CancerImmunotherapy #TranslationalResearch
๐งฌ Cell therapy in sarcoma: what do we know so far?
Our new #OpenAccess review in the ๐ ๐๐ฎ๐ฎ๐ถ๐ฏ๐ฐ๐ต๐ฉ๐ฆ๐ณ ๐๐ข๐ฏ๐ค๐ฆ๐ณ @sitcancer.bsky.social summarises the current landscape of cell therapy in sarcoma.
@tkoraysahin.bsky.social @lizconnolly.bsky.social
A big welcome to our #MedicalOncology colleagues from National Cancer Institute of Ukraine ๐บ๐ฆ. Looking forward to working with you all this week and beyond!
@mcrcnews.bsky.social
@christieinstitute.bsky.social
As featured in Technology Networks ๐
www.technologynetworks.com/tn/news/how-...
Congrats to the team of @reisesousalab.bsky.social for this beautiful work in @natimmunol.nature.com showing that "Neoantigen cross-presentation by cDC1 can determine the immune visibility of the tumor mutational landscape and sculpt cancer evolution by immunoediting"
www.nature.com/articles/s41...